Pieris Publication

Pulmonary Delivery of PRS-400 Anti-Jagged-1 Anticalin® Proteins Reduce Inflammation-Driven Goblet Cell Metaplasia and Mucus Hypersecretion in Vivo

Preclinical profile of PRS-220, a novel inhaled inhibitor of CTGF/CCN2, in clinical development for Idiopathic Pulmonary Fibrosis

Combination of cinrebafusp alfa with ramucirumab and paclitaxel is well tolerated and elicits encouraging clinical activity in patients with HER2-positive gastric/gastroesophageal junction (GEJ) adenocarcinoma

Development of PRS-400, an inhaled Jagged-1-specific Anticalin® protein for the treatment of muco-obstructive lung diseases. ERS 2022.

PRS-220, a novel inhalable therapeutic intervention for IPF, targeting CTGF directly in the lung. ATS 2022.

The Anticalin-antibody bispecific PRS-352/S095025 strongly stimulates human CD4+ T cells in a PD-L1–dependent manner. AACR 2022.

Development of PRS-220, a potential best-in-class, inhaled CTGF/CCN2 inhibitor for the treatment of IPF. ERS 2022.

Phase 1 Dose Escalation Study of PRS-343, a HER2/4-1BB Bispecific Molecule, in Patients with HER2+ Malignancies. AACR 2021.

Simultaneous costimulatory T-cell engagement and checkpoint inhibition by PRS- 344/S095012, a 4-1BB/PD-L1 bispecific compound for tumor-localized activation of the immune system. AACR 2021.

A Phase 1 Dose Escalation Study of PRS-343, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-positive Malignancies.ESMO 2020.